773094-77-2

Usage

Physical state

Colorless to pale yellow liquid

Uses

Intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Health hazards

Skin and eye irritant, harmful if swallowed or inhaled

Safety precautions

Handle with care and follow proper safety guidelines

Environmental impact

Limited water solubility, may accumulate in aquatic environments and pose risks

Upstream product

• 56990-02-4 3,5-dibromobenzaldehyde 
• 107-21-1 ethylene glycol 

Downstream Products

• 112538-48-4 3,5-diisopropyl benzaldehyde 
• 856651-56-4 3,5-dibutoxycarbonylbenzaldehyde 
• 871345-52-7 (4-carbamimidoyl-phenylamino)-[3-(tetrahydro-pyran-4-yloxy)-5-vinyl-phenyl]-acetic acid methyl ester 
• 871345-19-6 (4-carbamimidoyl-phenylamino)-[3-(tetrahydro-pyran-4-yloxy)-5-vinyl-phenyl]-acetic acid 
• 871345-39-0 (4-cyano-phenylamino)-[3-(tetrahydro-pyran-4-yloxy)-5-vinyl-phenyl]-acetic acid methyl ester 
• 871345-51-6 4-(3-[1,3]dioxolan-2-yl-5-vinyl-phenoxy)-tetrahydro-pyran 
• 871345-38-9 3-(tetrahydro-pyran-4-yloxy)-5-vinyl-benzaldehyde 
• 871345-37-8 3-[1,3]dioxolan-2-yl-5-vinyl-phenol 
• 871345-50-5 2-(3-bromo-5-vinyl-phenyl)-[1,3]dioxolane 
• 856651-70-2 5-[1,3]dioxolan-2-yl-isophthalic acid dibutyl ester 
• 909854-23-5 3-bromo-5-[1,3]dioxolan-2-yl-phenol 
• 1541198-97-3 2-(3-bromo-5-(1,3-dioxolan-2-yl)phenyl)acetonitrile 

Relevant academic research and scientific papers

META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS

The present disclosure provides pharmaceutical agents of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.

BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives

This invention is concerned with compounds of the formula wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors

We describe the structure-based design and synthesis of highly potent, orally bioavailable tissue factor/factor VIIa inhibitors which interfere with the coagulation cascade by selective inhibition of the extrinsic pathway.

Synthesis of symmetrical tetraaryltetranaphtho[2,3]porphyrins

A new method of synthesis of meso-tetraaryltetranaphtho[2,3]porphyrins (Ar4TNP) has been developed. Ar4TNPs with peripheral functional groups are obtained by oxidative aromatization of meso-tetraarylporphyrins in which pyrrole units